Sclerosis News and Research

RSS
First edition: September 15, 2009

First edition: September 15, 2009

Mellow Hope completes clinical trial of H1N1 vaccine, receives approval from SFDA

Mellow Hope completes clinical trial of H1N1 vaccine, receives approval from SFDA

American Scientific Resources acquires Safeguard Medical's home needle destruction device patent

American Scientific Resources acquires Safeguard Medical's home needle destruction device patent

New data confirm link between Epstein-Barr virus and multiple sclerosis

New data confirm link between Epstein-Barr virus and multiple sclerosis

Mylan Pharmaceutical's ANDA for Teva's Copaxone accepted by FDA (Correction)

Mylan Pharmaceutical's ANDA for Teva's Copaxone accepted by FDA (Correction)

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

New findings could yield effective therapies for multiple sclerosis

New findings could yield effective therapies for multiple sclerosis

Results further support the benefits of TYSABRI for multiple sclerosis patients

Results further support the benefits of TYSABRI for multiple sclerosis patients

Master gene could lead to new ways of cancer treatments

Master gene could lead to new ways of cancer treatments

Obama's interview on health and fitness priorities to be published in a health magazine

Obama's interview on health and fitness priorities to be published in a health magazine

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

AVONEX results in fewer injection site reactions, according to a clinical study

AVONEX results in fewer injection site reactions, according to a clinical study

Mayo study raises hope for treating multiple sclerosis

Mayo study raises hope for treating multiple sclerosis

Neurologists recommend oral cladribine for treating multiple sclerosis

Neurologists recommend oral cladribine for treating multiple sclerosis

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx granted patent for molecular chaperone amplifier drug candidate

Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis

Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Human neural stem cells to treat Pelizaeus-Merzbacher Disease

Human neural stem cells to treat Pelizaeus-Merzbacher Disease

BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.